Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | NGFR | P08138 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL888365 | 0.83 | CYP1A2 (0.41) | KDM4EHSD17B10ALDH1A1HPGDMEN1 | |
| SCHEMBL124755 | 0.76 | KDM4E (0.48) | KDM4EHSD17B10ALDH1A1LMNANGFR | |
| SCHEMBL11739512 | 0.74 | KDM4E (0.49) | KDM4EHSD17B10ALDH1A1LMNANGFR | |
| SCHEMBL11742831 | 0.74 | KDM4E (0.49) | KDM4EHSD17B10ALDH1A1LMNANGFR | |
| SCHEMBL24190120 | 0.72 | KDM4E (0.47) | KDM4EHSD17B10ALDH1A1LMNANGFR | |
| SCHEMBL6753336 | 0.72 | KDM4E (0.47) | KDM4EHSD17B10ALDH1A1LMNANGFR | |
| SCHEMBL6321534 | 0.69 | KDM4E (0.43) | KDM4EHSD17B10ALDH1A1LMNANGFR | |
| SCHEMBL4811922 | 0.69 | KDM4E (0.47) | KDM4EHSD17B10ALDH1A1LMNANGFR | |
| SCHEMBL9970255 | 0.68 | GPR35 (0.51) | KDM4EHSD17B10ALDH1A1LMNAHPGD | |
| SCHEMBL6838149 | 0.67 | KDM4E (0.56) | KDM4EHSD17B10ALDH1A1LMNANGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117126846-A | Oligonucleotide conjugates | 罗氏创新中心哥本哈根有限公司 | 2023-11-28 | — | — | CN | disclosed |
| US-11155816-B2 | Oligonucleotide conjugates | ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) | 2021-10-26 | — | — | US | disclosed |
| US-20210238601-A1 | Oligonucleotide Conjugates | ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) | 2021-08-05 | — | — | US | disclosed |
| US-10358643-B2 | Poly oligomer compound with biocleavable conjugates | HOFFMANN-LA ROCHE, INC. (US) | 2019-07-23 | — | — | US | disclosed |
| EP-3406718-A1 | OLIGONUCLEOTIDE CONJUGATES | Roche Innovation Center Copenhagen A/S (DK) | 2018-11-28 | — | — | EP | disclosed |
| US-10077443-B2 | Oligonucleotide conjugates | ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) | 2018-09-18 | — | — | US | disclosed |
| US-20180251764-A1 | Oligonucleotide Conjugates | ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) | 2018-09-06 | — | — | US | disclosed |
| US-20170349896-A1 | POLY OLIGOMER COMPOUND WITH BIOCLEAVABLE CONJUGATES | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2017-12-07 | — | — | US | disclosed |
| US-20150275212-A1 | Oligonucleotide Conjugates | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2015-10-01 | — | — | US | disclosed |
| US-20090203132-A1 | PYRROLIDINYL GROUPS FOR ATTACHING CONJUGATES TO OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. | 2009-08-13 | — | — | US | disclosed |
| US-20080199960-A1 | Methods for the Delivery of Oligomeric Compounds | K.U. LEUVEN RESEARCH AND DEVELOPMENT (BE) | 2008-08-21 | — | — | US | disclosed |
| WO-2005113571-A2 | METHODS FOR THE DELIVERY OF OLIGOMERIC COMPOUNDS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050119470-A1 | Conjugated oligomeric compounds and their use in gene modulation | ISIS PHARMACEUTICALS, INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203132-A1 | PYRROLIDINYL GROUPS FOR ATTACHING CONJUGATES TO OLIGOMERIC COMPOUNDS | PHAX, RIOX2, RNMT | KDM4E 3818/4885HSD17B10 3581/4885ALDH1A1 3432/4885 |
| US-20050119470-A1 | Conjugated oligomeric compounds and their use in gene modulation | PHAX, SNRPE, RRP1B | KDM4E 4254/4885HSD17B10 1469/4885ALDH1A1 3271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.